stars 1 stars 2 stars 3

Regenaxis Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapies to regenerate myelin and restore function in demyelinating diseases of the central nervous system. With a novel therapeutic approach targeting the biological mechanisms of remyelination, we aim to address a critical unmet need in neurology and unlock new therapeutic opportunities in neurodegeneration.

Employees 2 (1 on RocketReach)
Founded 2025
Industry Biotechnology Research

Regenaxis Therapeutics Questions

Nabil Osmani is the CEO and Co-founder of Regenaxis Therapeutics.

1 people are employed at Regenaxis Therapeutics.

Top Regenaxis Therapeutics Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users